Amgen will buy Celgene drug in $13.4B antitrust sale

AMGEN ANNOUNCED that it will purchase the drug Otezla from Celgene Corp. for $13.4 billion in cash. / BLOOMBERG NEWS FILE PHOTO
BOSTON – Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co. The all-cash deal will give Amgen a growing product at a time when the blockbuster biotechnology drugs it…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display